FREE CONSULTATION (713) 621-7944


Transvaginal Mesh Trial Plaintiff Rested: Now It’s Johnson & Johnson’s Turn

January 1, 1970 · FLEMING | NOLEN | JEZ, L.L.P.

On Tuesday, the plaintiff rested her case. But before turning the reigns over to Johnson & Johnson’s defense attorneys, plaintiffs’ counsel presented powerful testimony from two Ethicon, a Johnson & Johnson company, employees:

1. Scott Jones, sales manager.

  • Mr. Jones testified that Prolift transvaginal mesh was marketed to less skilled physicians.
  • He admitted that the company needed to improve physician training and education.

2. Dr. David Robinson, the medical director.

  • Dr. Robinson admitted that he was aware the Prolift transvaginal mesh could retract and cause injury to patients.
  • Dr. Robinson also testified that he cautioned the company about creating a registry to track adverse events that occurred with Prolift transvaginal mesh because it would make competitors’ product appear safer and the company would lose market share.
  • He further admitted that Ethicon, a Johnson & Johnson company, knew that dyspareunia (pain with intercourse) was a known adverse event but was NOT mentioned in the patient brochure for Prolift transvaginal mesh.
  • Dr. Robinson admitted that the company knew that Prolift transvaginal mesh had an erosion rate of 19% and that was acceptable.

Johnson & Johnson called its urogynecology expert, Dr. Miles Murphy, and is likely to try to shift the focus to the plaintiff and her medical history. Stay tuned for more…